TY - JOUR
T1 - Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up
AU - van der Valk, Mirthe E.
AU - Mangen, Marie-Josee J.
AU - Severs, Mirjam
AU - van der Have, Mike
AU - Dijkstra, Gerard
AU - van Bodegraven, Ad A.
AU - Fidder, Herma H.
AU - de Jong, Dirk J.
AU - van der Woude, C. Janneke
AU - Romberg-Camps, Marielle J. L.
AU - Clemens, Cees H. M.
AU - Jansen, Jeroen M.
AU - de Meeberg, Paul C. van
AU - Mahmmod, Nofel
AU - van der Meulen-de Jong, Andrea E.
AU - Ponsioen, Cyriel Y.
AU - Bolwerk, Clemens
AU - Vermeijden, J. Reinoud
AU - Siersema, Peter D.
AU - Leenders, Max
AU - Oldenburg, Bas
AU - COIN Study Grp
AU - Dutch Initiative on Crohn and Colitis
PY - 2016/4/21
Y1 - 2016/4/21
N2 - BackgroundWith the increasing use of anti-TNF therapy in inflammatory bowel disease (IBD), a shift of costs has been observed with medication costs replacing hospitalization and surgery as major cost driver. We aimed to explore the evolution of IBD-related costs over two years of follow-up.Methods and FindingsIn total 1,307 Crohn's disease (CD) patients and 915 ulcerative colitis (UC) patients were prospectively followed for two years by three-monthly web-based questionnaires. Changes of healthcare costs, productivity costs and out-of-pocket costs over time were assessed using mixed model analysis. Multivariable logistic regression analysis was used to identify costs drivers. In total 737 CD patients and 566 UC were included. Total costs were stable over two years of follow-up, with annual total costs of (sic)7,835 in CD and (sic)3,600 in UC. However, within healthcare costs, the proportion of anti-TNF therapy-related costs increased from 64% to 72% in CD (pConclusionsBD-related costs remained stable over two years. However, the proportion of anti-TNF-related healthcare costs increased, while hospitalization costs decreased. Factors associated with increased costs were penetrating disease course in CD and age
AB - BackgroundWith the increasing use of anti-TNF therapy in inflammatory bowel disease (IBD), a shift of costs has been observed with medication costs replacing hospitalization and surgery as major cost driver. We aimed to explore the evolution of IBD-related costs over two years of follow-up.Methods and FindingsIn total 1,307 Crohn's disease (CD) patients and 915 ulcerative colitis (UC) patients were prospectively followed for two years by three-monthly web-based questionnaires. Changes of healthcare costs, productivity costs and out-of-pocket costs over time were assessed using mixed model analysis. Multivariable logistic regression analysis was used to identify costs drivers. In total 737 CD patients and 566 UC were included. Total costs were stable over two years of follow-up, with annual total costs of (sic)7,835 in CD and (sic)3,600 in UC. However, within healthcare costs, the proportion of anti-TNF therapy-related costs increased from 64% to 72% in CD (pConclusionsBD-related costs remained stable over two years. However, the proportion of anti-TNF-related healthcare costs increased, while hospitalization costs decreased. Factors associated with increased costs were penetrating disease course in CD and age
KW - POPULATION-BASED COHORT
KW - HEALTH-CARE COSTS
KW - CROHNS-DISEASE
KW - ULCERATIVE-COLITIS
KW - RHEUMATOID-ARTHRITIS
KW - INCEPTION COHORT
KW - CLINICAL-COURSE
KW - ILLNESS
KW - PREDICTORS
KW - SWEDEN
U2 - 10.1371/journal.pone.0142481
DO - 10.1371/journal.pone.0142481
M3 - Article
C2 - 27099937
SN - 1932-6203
VL - 11
JO - PLoS ONE
JF - PLoS ONE
IS - 4
M1 - e0142481
ER -